131 I-抗CEA单克隆抗体卵巢癌病人放射免疫显像体内动力学研究

目的：探讨^131I-抗CEA McAb(C50)卵巢癌病人放射免疫显像中血药动力学的特性。方法：43例卵巢癌病人放射免疫显像前后分别测定血清中CEA含量,标记抗体循环血液中分布,T／NT比值,标记抗体放射性半排时间及病人人抗鼠抗体的产生。结果：标记抗体主要分布于血浆蛋白中,^131I-C50循环血液中的半清时间平均为23h,尿中放射性半清时间为24h,卵巢癌病人在接受标记抗体后2－3周即可产生人抗鼠抗体,在体内至少维持9月以上。结论：标记抗体血药动力学的研究可指导放射免疫显像的应用,抗鼠抗体的产生影响了二次显像效果,限制了鼠源性单抗的反复应用。

Biokinetics of 131 I-labelled monclonal antibodies against CEA in ovarian cancer patients

Objective: To Probe into the biokinetics of 131 I-Labelled monoclonal antibodies against CEA in 43 ovarian cancer patients who received labelled antibody in diagnostic immunoscintigraphy trials. Method: The CEA in plasma, the distribution and half-life of radio-labeled antibody in circulation and the ratio of T/NT were measured in 28 ovarian cancer patients after radioimmunoscintigraphy. Detection of the anti-mouse-IgG antibody was also conducted. Result: Blood-borne radioactivity was associated predominantly with plasma rather than celluar elements. A bi-phasic decline of radiolabelled antibody ( 131I-C50) was mearured with a half life of 23 hours. Urinary excretion of radioactivity was measured with a half life of 24 hours. Human anti-mouse-IgG antibody (HAMA) was detected 2-3weeks after adminstration of radiolabelled antibody and was present for at least 9 months. Conclusion: The result provides guidance for clinical application of radioimmunoscintigraphy in ovarian cancer, HAMA produces limitations to the efficiency of repeated image studies.